



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Darrell R. Anderson, et al.

Group Art Unit: 1644

Application No. 09/758,173

Filed: January 12, 2001

Title: HUMAN B7.1 SPECIFIC PRIMATIZED ANTIBODIES AND TRANSFECTOMAS
EXPRESSING SAID ANTIBODIES

* * * * *

REQUEST TO USE COMPUTER READABLE
SEQUENCE LISTING FORM FROM PARENT APPLICATION

RECEIVED

Hon. Commissioner of Patents
2022 South Clark Place
Crystal Plaza Two, Lobby, Room 1B03, Box Sequence
Arlington, VA 22202
ATTN: CUSTOMER WINDOW

APR 15 2002

TECH CENTER 1600/2900

Sir:

Applicants advise that the computer readable form in the above-identified application is identical with that filed in U.S. Serial No. 09/383,916, filed August 26, 1999, which is a divisional of U.S. Serial No. 08/487,550, filed June 7, 1995.

Accordingly, in accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed in the parent application, Serial No. 09/383,916, as the computer readable form for the instant application. It is understood that the U.S. Patent & Trademark Office will make the necessary change in application and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing, as filed in the parent application, is to be incorporated into the present specification.

Respectfully submitted,

Pillsbury Winthrop LLP

Date: 9/12/02

By: R. L. T.

Robin L. Teskin
Registration No. 35,030

1600 Tysons Boulevard
McLean, VA 22102
(703) 905-2200 Telephone
(703) 905-2500 Facsimile

Inventor(s): ANDERSON et al.
 Appln. No.: 09 | 758,173
 Series Code ↑ | Serial No. ↑

Group Art Unit 1644
 Examiner: Gambel
 Atty. Dkt. P 276603 | 1995-30-0233C2
 M# | Client Ref

Filed: January 12, 2001

Hon. Commissioner of Patents
 Washington, D.C. 20231

Sir:

REPLY/AMENDMENT/LETTER



Appln. Title: HUMAN B7.1 SPECIFIC PRIMATIZED
 ANTIBODIES AND TRANSFECTOMAS
 EXPRESSING SAID ANTIBODIES

RECEIVED

Date: April 12, 2002 APR 15 2002

TECH CENTER 1600/2600

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment(s) made a part hereof, which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim	For B & C See Required Separate Paper (Pat-256)
A. <input checked="" type="checkbox"/> NOT made	
B. <input type="checkbox"/> Withdrawn	
C. <input type="checkbox"/> made herewith	
D. <input type="checkbox"/> made previously	

	Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	16	**minus 20		x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	1	***minus 3	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)		add	+ \$280/\$140 =	+ \$0		104/204
5. Original due Date: April 12, 2002	<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached	(1 mo) (2 mos) (3 mos)	\$110/\$55 = \$400/\$200 = \$920/\$460 =	+ \$0			115/215 116/216 117/217 118/218 128/228
	(Usable only for ≤ 2mo.OA --- 4 mos) (Usable only for 30 day/1mo.OA --- 5 mos)	\$1,440/\$720=				
		\$1,960/\$980=				
7. Enter any previous extension fee paid since above original due date and subtract		- \$0				
8.		Extension Fee Attached	+ \$0			
9. If Terminal Disclaimer attached, add Rule 20(d) official fee		+ \$110/\$55	+ \$0			148/248
10. If IDS attached requires Official Fee under Rule 97 (c), or if Rule 97(d) Request	add add	+ \$180 + \$180	+ \$0 + \$0			126 126
11. After-Final Request Fee per rules 129(a) and 17(r)		+ \$740/370	+ \$0			146/246
12. No. of additional inventions for examination per Rule 129(b)		x \$740/370 ea	+ \$0			149/249
13. Request for Continued Examination (RCE)		+ \$740/370	+ \$0			1179/1279
14. Request for Use Computer Readable Sequence Listing Form From Parent Application		+ \$0				
15.		TOTAL FEE ENCLOSED =	\$0			

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 037003 | 276603
C# | M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
 Intellectual Property Group

By Atty: Robin L. Teskin

Sig: 

Reg. No. 35,030

Fax: (703) 905-2500
 Tel: (703) 905-2200

1600 Tysons Boulevard
 McLean, VA 22102
 Tel: (703) 905-2000

Atty/Sec: RLT/AF

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments